Revelation Biosciences (REVB) Q2 2025 earnings summary

Executive summary

• Focused on developing Gemini-based therapies for acute kidney injury, chronic kidney disease, and post-surgical infection, with no revenue generated to date.

• Completed dosing in PRIME Phase 1b Clinical Study of Gemini in CKD patients.

• Cash and cash equivalents stood at $5.2 million as of June 30, 2025, expected to fund operations through December 2025.

• Accumulated deficit reached $45.0 million as of June 30, 2025, with a net loss of $4.5 million for the six months ended June 30, 2025.

Financial highlights

• Net loss for the six months ended June 30, 2025 was $4.5 million, compared to $11.1 million for the same period in 2024.

• Net loss for Q2 2025 was $2.4 million, a significant improvement from $8.4 million in Q2 2024.

• Operating expenses for the six months ended June 30, 2025 were $4.6 million, up from $4.4 million year-over-year.

• Cash used in operating activities was $4.7 million for the six months ended June 30, 2025.

• Net cash provided by financing activities was $3.4 million, primarily from the May 2025 public offering.

Outlook and guidance

• Expects to continue incurring significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future.

• Current cash position expected to fund operations through December 2025.

• Plans to seek additional funding through public or private equity or debt financings; failure to secure funding may delay or halt development programs.

• Anticipates announcing data from the Phase 1b study later in Q3 2025.

• Plans to engage with the FDA later in 2025 to advance Gemini's clinical development.